Invesco
ADPT icon

Invesco’s Adaptive Biotechnologies ADPT Stock Holding History

Invesco’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.4M Sell
3,094,011
-1,356,055
-30% -$20.8M 0.01% 1034
2026
Q1 		$61.8M Buy
4,450,066
+1,342,413
+43% +$21.4M 0.01% 996
2025
Q4 		$50.5M Buy
3,107,653
+2,216,595
+249% +$36.2M ﹤0.01% 1080
2025
Q3 		$13.3M Sell
891,058
-17,356
-2% -$211K ﹤0.01% 1655
2025
Q2 		$10.6M Buy
908,414
+355,883
+64% +$3.23M ﹤0.01% 1741
2025
Q1 		$4.11M Buy
552,531
+378,940
+218% +$2.91M ﹤0.01% 2254
2024
Q4 		$1.04M Buy
173,591
+4,985
+3% +$27.5K ﹤0.01% 2904
2024
Q3 		$863K Sell
168,606
-3,254
-2% -$14.2K ﹤0.01% 2975
2024
Q2 		$622K Sell
171,860
-2,696
-2% -$8.56K ﹤0.01% 3182
2024
Q1 		$560K Buy
174,556
+66,015
+61% +$255K ﹤0.01% 3272
2023
Q4 		$532K Buy
108,541
+1,215
+1% +$5.54K ﹤0.01% 3179
2023
Q3 		$585K Sell
107,326
-2,860
-3% -$18.9K ﹤0.01% 3126
2023
Q2 		$739K Buy
110,186
+3,775
+4% +$28.1K ﹤0.01% 3036
2023
Q1 		$940K Buy
106,411
+12,316
+13% +$109K ﹤0.01% 2928
2022
Q4 		$719K Buy
94,095
+2,380
+3% +$18.5K ﹤0.01% 3096
2022
Q3 		$653K Sell
91,715
-2,780
-3% -$26.2K ﹤0.01% 3108
2022
Q2 		$764K Sell
94,495
-51,305
-35% -$451K ﹤0.01% 3112
2022
Q1 		$2.02M Sell
145,800
-1,403,282
-91% -$22.1M ﹤0.01% 2783
2021
Q4 		$43.5M Buy
1,549,082
+36,538
+2% +$1.12M 0.01% 1108
2021
Q3 		$51.4M Sell
1,512,544
-20,090
-1% -$727K 0.01% 1038
2021
Q2 		$62.6M Buy
1,532,634
+213,167
+16% +$8.29M 0.02% 990
2021
Q1 		$53.1M Sell
1,319,467
-204,963
-13% -$11.1M 0.01% 1035
2020
Q4 		$90.1M Buy
1,524,430
+254,801
+20% +$13.1M 0.03% 779
2020
Q3 		$61.7M Buy
1,269,629
+38,792
+3% +$1.63M 0.02% 843
2020
Q2 		$59.5M Buy
1,230,837
+1,006,018
+447% +$36.7M 0.02% 823
2020
Q1 		$6.25M Sell
224,819
-30,549
-12% -$852K ﹤0.01% 1765
2019
Q4 		$7.64M Buy
255,368
+25,614
+11% +$736K ﹤0.01% 1917
2019
Q3 		$7.1M Buy
229,754
+4,754
+2% +$194K ﹤0.01% 1922
2019
Q2 		$10.9M Buy
+225,000
New +$9.97M ﹤0.01% 1708

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco's ADPT Position: Q2 2026 in Review

Invesco reduced its Adaptive Biotechnologies (ADPT) stake by 30% in Q2 2026, selling an estimated $20.8M and leaving 3,094,011 shares worth $66.4M. The position accounts for 0.01% of the portfolio, ranked #1034.

Invesco first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $90.1M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Invesco held 3,094,011 shares of Adaptive Biotechnologies worth $66.4M as of Q2 2026.
  • Invesco sold 1,356,055 Adaptive Biotechnologies shares in Q2 2026, an estimated $20.8M.
  • Adaptive Biotechnologies made up 0.01% of Invesco's portfolio in Q2 2026, its #1034 holding.
  • Invesco first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • Invesco's Adaptive Biotechnologies position peaked at $90.1M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.